GSK-3 and the neurodevelopmental hypothesis of schizophrenia

European Neuropsychopharmacology

Volumn 12, Issue 1, 2002, Pages 13-25

  Kozlovsky, Nitsan ^a   Belmaker, R H ^b   Agam, Galila ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b MINISTRY OF HEALTH   (Israel)

Author keywords

Apoptosis; Glycogen synthase kinase 3 (GSK 3); Neurodevelopmental hypothesis; Schizophrenia; Wnt signaling

Indexed keywords

BETA CATENIN; CASEIN KINASE I; CELL ADHESION MOLECULE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; HIGH MOBILITY GROUP PROTEIN; ISOPROTEIN; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN 1; MICROTUBULE ASSOCIATED PROTEIN 5; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFILAMENT PROTEIN; NEUROMODULIN; PHOSPHATIDYLINOSITOL 3 KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; SYNAPSIN I; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG; WNT 7A PROTEIN; WNT PROTEIN; WNT1 PROTEIN; WNT3 PROTEIN; WNT5A PROTEIN;

APOPTOSIS; BRAIN DEVELOPMENT; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HYPOTHESIS; NERVE CELL DIFFERENTIATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASES; HUMANS; SCHIZOPHRENIA;

EID: 0036154321     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(01)00131-6     Document Type: Review

References (149)

1. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development
2. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development
3. Does dysregulation of the Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease?
4. Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions
5. Abnormal expression of two microtubule-associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia
6. Recent advances in defining the neuropathology of schizophrenia
7. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
8. Decreased expression of the embryonic form of the neural cell adhesion molecule in schizophrenic brains
9. Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia
10. Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics
11. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients
12. Advancing a neurodevelopmental origin for schizophrenia
13. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21
14. Changes of synaptic density in the primary visual cortex of the macaque monkey from fetal to adult stage
15. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity
16. Gestational and neonatal factors in the etiology of schizophrenia
17. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics
18. Attenuation of microtubule-associated protein 1B expression by antisense oligodeoxynucleotides inhibits initiation of neurite outgrowth
19. Neurodevelopmental hypothesis of schizophrenia
20. New morphological and neuropathological findings in schizophrenia: A neurodevelopmental perspective
21. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
22. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons
23. The role of protein phosphorylation in the hormonal control of enzyme activity
24. Schizophrenia and the hippocampus: The embryological hypothesis extended
25. Abnormalities of Wnt signalling in schizophrenia - Evidence for neurodevelopmental abnormality
26. Alterations in hippocampal non-phosphorylated MAP2 protein expression in schizophrenia
27. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
28. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
29. A Darwinian approach to the origins of psychosis
30. IQ and risk for schizophrenia: A population-based cohort study
31. Wnt-5a and Wnt-7a are expressed in the developing chick limb bud in a manner suggesting roles in pattern formation along the proximodistal and dorsoventral axes
32. Negative regulation of Jun/AP-1: Conserved function of glycogen synthase kinase 3 and the Drosophila kinase shaggy
33. Role of glycogen synthase kinase 3 beta as a negative regulator of dorsoventral axis formation in Xenopus embryos
34. Ultrastructural localization of SNAP-25 within the rat spinal cord and peripheral nervous system
35. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia
36. Hippocampal and cortical growth-associated protein-43 messenger RNA in schizophrenia
37. A quantitative analysis of synaptogenesis in the molecular layer of the dentate gyrus in the rhesus monkey
38. Cell adhesion molecules in the regulation of animal form and tissue pattern
39. Limbic pathology in schizophrenia: The entorhinal region - A morphometric study
40. A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression
41. Changes in microtubule-associated protein MAP1B phosphorylation during rat brain development
42. Infant predictors of the longitudinal course of schizophrenic development
43. Implication of cyclin-dependent kinases and glycogen synthase kinase 3 in the phosphorylation of microtubule-associated protein 1B in developing neuronal cells
44. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity
45. Methodological issues in the neuropsychological approach to schizophrenia
46. Glycogen synthase kinase 3beta phosphorylation of microtubule-associated protein 1B regulates the stability of microtubules in growth cones
47. Confirming unexpressed genotypes for schizophrenia. Risks in the offspring of Fischer's Danish identical and fraternal discordant twins
48. Minor physical anomalies in schizophrenia
49. Phosphorylation of bovine neurofilament proteins by protein kinase FA (glycogen synthase kinase 3)
50. Differential cellular phosphorylation of neurofilament heavy side-arms by glycogen synthase kinase-3 and cyclin-dependent kinase-5
51. New genetic hypothesis of schizophrenia
52. Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling
53. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase
54. The neuropathology of schizophrenia. A critical review of the data and their interpretation
55. Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos
56. Phosphorylation of the type-II regulatory subunit of cyclic-AMP-dependent protein kinase by glycogen synthase kinase 3 and glycogen synthase kinase 5
57. Sequence of a cDNA clone encoding the polysialic acid-rich and cytoplasmic domains of the neural cell adhesion molecule N-CAM
58. The role of obstetric complications in schizophrenia
59. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation
60. The slow component of axonal transport. Identification of major structural polypeptides of the axon and their generality among mammalian neurons
61. Identification of multifunctional ATP-citrate lyase kinase as the alpha-isoform of glycogen synthase kinase-3
62. A decrease of reelin expression as a putative vulnerability factor in schizophrenia
63. Hippocampal pathologic findings in schizophrenia. A morphometric study
64. Cortical development and neuropathology in schizophrenia
65. Child development risk factors for adult schizophrenia in the British 1946 birth cohort
66. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: A possible neurochemical basis for 'hypofrontality'
67. SDS-PAGE strongly overestimates the molecular masses of the neurofilament proteins
68. A molecular mechanism for the effect of lithium on development
69. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients
70. Low GSK-3 activity in frontal cortex of schizophrenic patients
71. Polysialic acid as a regulator of intramuscular nerve branching during embryonic development
72. The specification of dorsal cell fates in the vertebrate central nervous system
73. Developmental expression and localization of glycogen synthase kinase-3beta in rat brain
74. Obstetric complications, neurodevelopmental deviance, and risk of schizophrenia
75. Qualitative assessment of brain morphology in acute and chronic schizophrenia
76. Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1
77. Minor physical anomalies in schizophrenia and mood disorders
78. WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons
79. Identification of two protein kinases that phosphorylate the neural cell-adhesion molecule, N-CAM
80. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau
81. The microtubule cytoskeleton and the development of neuronal polarity
82. Age disorientation in schizophrenia: An indicator of progressive and severe psychopathology, not institutional isolation
83. Microtubule-associated proteins in the developing brain
84. MRI anatomy of schizophrenia
85. A neural cell adhesion molecule from human brain
86. The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain
87. Adult schizophrenia following prenatal exposure to an influenza epidemic
88. An overview of the mechanism of action of clozapine
89. Cytoskeletal dynamics and nerve growth
90. Increased expression of Wnt-1 in schizophrenic brains
91. WNTs modulate cell fate and behavior during vertebrate development
92. Neurodevelopmental schizophrenia: The rediscovery of dementia praecox
93. The neuronal growth-associated protein GAP-43 (B-50, F1): Neuronal specificity, developmental regulation and regional distribution of the human and rat mRNAs
94. A versatile transcriptional effector of Wingless signaling
95. Wnt genes: Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome
96. Cell death during development of the nervous system
97. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics
98. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway
99. Wnt genes and vertebrate development
100. Roles of wnt proteins in neural development and maintenance
101. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes
102. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia
103. Signalling at a distance: Transport of Wingless in the embryonic epidermis of Drosophila
104. Human homologue sequences to the Drosophila dishevelled segment-polarity gene are deleted in the DiGeorge syndrome
105. Glycogen synthase kinase-3: Functions in oncogenesis and development
106. Radiation hybrid mapping of genes in the lithium-sensitive wnt signaling pathway
107. Schizophrenia: The cellular biology of a functional psychosis
108. Delineation of 7q11.2 deletions associated with Williams-Beuren syndrome and mapping of a repetitive sequence to within and to either side of the common deletion
109. Expression of two members of the Wnt family during mouse development-restricted temporal and spatial patterns in the developing neural tube
110. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly
111. Isolation and chromosomal mapping of human glycogen synthase kinase-3 alpha and -3 beta encoding genes
112. Retinoic acid induces down-regulation of Wnt-3a, apoptosis and diversion of tail bud cells to a neural fate in the mouse embryo
113. Wingless signaling acts through zeste-white 3, the Drosophila homolog of glycogen synthase kinase-3, to regulate engrailed and establish cell fate
114. The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor
115. Wnt signaling and dorso-ventral axis specification in vertebrates
116. Increased levels of GAP-43 protein in schizophrenic brain tissues demonstrated by a novel immunodetection method
117. Potential mechanism(s) involved in the regulation of glycogen synthesis by insulin
118. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
119. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation
120. Monoclonal antibodies distinguish phosphorylated and nonphosphorylated forms of neurofilaments in situ
121. Abnormal reinnervation as a basis for schizophrenia: A hypothesis
122. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome
123. Synapsin I, synapsin II, and synaptophysin: Marker proteins of synaptic vesicles
124. Cell adhesion molecules in early chicken embryogenesis
125. Targeted disruption of the murine int-1 proto-oncogene resulting in severe abnormalities in midbrain and cerebellar development
126. Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia
127. Seasonality of schizophrenia and stillbirths
128. The stanley foundation brain collection and neuropathology consortium
129. Schizophrenia: Genes and environment
130. Further studies of elevated cerebrospinal fluid neuronal cell adhesion molecule in schizophrenia
131. Rabbit skeletal muscle protein phosphatase(s). Identity of phosphorylase and synthase phosphatase and interconversion to the ATP-Mg-dependent enzyme form
132. Abnormal expression of cell recognition molecules in schizophrenia
133. Use of a synthetic peptide as a selective substrate for glycogen synthase kinase 3
134. A large family of putative transmembrane receptors homologous to the product of the Drosophila tissue polarity gene frizzled
135. The NOTCH4 locus is associated with susceptibility to schizophrenia
136. Implications of normal brain development for the pathogenesis of schizophrenia
137. Computed tomography in schizophreniform disorder and other acute psychiatric disorders
138. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B
139. Mechanisms of Wnt signaling in development
140. Molecular cloning and expression of glycogen synthase kinase-3/factor A
141. A common denominator linking glycogen metabolism, nuclear oncogenes and development
142. Identification of the ATP-Mg-dependent protein phosphatase activator (FA) as a myelin basic protein kinase in the brain
143. Identification and characterization of an ATP-Mg-dependent protein phosphatase from pig brain
144. Protein kinase FA/glycogen synthase kinase 3 alpha predominantly phosphorylates the in vivo sites of Ser502, Ser506, Ser603, and Ser666 in neurofilament
145. Identification of the ATP.Mg-dependent protein phosphatase activator (FA) as a synapsin I kinase that inhibits cross-linking of synapsin I with brain microtubules
146. Dysfunction of protein kinase FA/GSK-3 alpha in lymphocytes of patients with schizophrenic disorder
147. SNAP-25 deficit and hippocampal connectivity in schizophrenia
148. Immunological and biochemical study on tissue and subcellular distributions of protein kinase FA (an activating factor of ATP-Mg-dependent protein phosphatase): A simplified and efficient procedure for high quantity purification from brain
149. Ventricular enlargement in schizophrenia: Is there really a gender effect?